Levobetaxolol ophthalmic Pregnancy and Breastfeeding Warnings
Brand names: Betaxon
Levobetaxolol ophthalmic Pregnancy Warnings
Levobetaxolol ophthalmic has been assigned to pregnancy category C by the FDA. Animal studies have failed to reveal evidence of teratogenicity, but increased post-implantation loss occurred at 12 mg/kg/day and an increased incidence of sternebrae malformations occurred at 4 mg/kg/day in rats and rabbits. There are no controlled data during human pregnancy. Levobetaxolol is only recommended for use during pregnancy when benefit outweighs risk.
Levobetaxolol ophthalmic Breastfeeding Warnings
There are no data on the excretion of levobetaxolol into human milk. Racemic betaxolol has been reported to be excreted into human milk after oral administration. Other beta-blockers and topical timolol maleate are excreted in milk. In general, most experts recommend monitoring of nursing infants for signs and symptoms of beta-blockade, such as bradycardia and hypoglycemia. The manufacturer recommends caution when administering levobetaxolol ophthalmic to nursing women.
References for pregnancy information
- (2001) "Product Information. Betaxon (levobetaxolol ophthalmic)." Alza
References for breastfeeding information
- (2001) "Product Information. Betaxon (levobetaxolol ophthalmic)." Alza
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
